Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Appointed director
Quarterly results
CC transcript
ENDOLOGIX INC (ELGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/01/2020 8-K Quarterly results
09/22/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "First Lien Claims",
"First Lien Claims"
07/09/2020 8-K Quarterly results
07/06/2020 8-K Quarterly results
07/01/2020 8-K Quarterly results
06/24/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
06/15/2020 8-K Entry into a Material Definitive Agreement
Docs: "Not Applicable Former name or former address, if changed since last report"
06/11/2020 8-K Submission of Matters to a Vote of Security Holders
05/11/2020 8-K Quarterly results
04/27/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/07/2020 8-K Other Events
03/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED BYLAWS OF ENDOLOGIX, INC.",
"Endologix Adds Jane E. Kiernan to its Board of Directors"
03/16/2020 8-K Quarterly results
02/24/2020 8-K Quarterly results
02/19/2020 8-K Quarterly results
12/18/2019 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Endologix Reports Third Quarter 2019 Financial Results Third Quarter Highlights • Global revenue up 2.9% versus prior year • Sequential AFX system sales increase in the U.S. • Operating cash burn of $4.0M for the quarter"
11/01/2019 8-K Quarterly results
08/22/2019 8-K Termination of a Material Definitive Agreement
Docs: "Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share ELGX The Nasdaq Stock Market, LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 of the Exchange Act. ☐ Item 1.02 Termination of a Material Definitive Agreement. On August 22, 2019, Endologix, Inc. delivered written notice to Piper Jaffray & Co. , effective as of such date, to te..."
08/13/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share ELGX The Nasdaq Stock Market, LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement.",
"Opinion of DLA Piper LLP (US)",
"Equity Distribution Agreement, by and between Endologix, Inc. and Piper Jaffray & Co"
08/09/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
06/12/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/10/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/02/2019 8-K Quarterly results
Docs: "Endologix Reports First Quarter 2019 Financial Results"
04/04/2019 8-K Other Events
Docs: "FORM 8-K"
04/01/2019 8-K Credit agreement amendment
Docs: "Form of Pre-Paid Warrant to Purchase Common Stock",
"Form of Amended and Restated Initial (2017) Warrant",
"Form of Amended and Restated Additional (2018) Warrant",
"Form of First Out Waterfall Note",
"Form of Indenture in respect of 5.00% Mandatory Convertible Senior Notes due 2024",
"Form of 5.00% Mandatory Convertible Senior Note due 2024",
"Form of Indenture in respect of 5.00% Voluntary Convertible Senior Notes due 2024",
"Form of 5.00% Voluntary Convertible Senior Note due 2024",
"Opinion of DLA Piper LLP (US)",
"Purchase Agreement, among Endologix, Inc. and the investors named on Schedule I thereto"
03/05/2019 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF ENDOLOGIX, INC., a Delaware corporation ENDOLOGIX, INC., a Delaware corporation, organized and existing under and by virtue of the Delaware General Corporation Law , does hereby certify that: FIRST: The name of the corporation is Endologix, Inc. . SECOND: The Board of Directors of the Corporation has duly adopted resolutions proposing and declaring advisable the following amendment to the Amended and Restated Certificate of Incorporation of the Corporation, as amended , directing that said amendment be submitted to the stockholders of the Corporation for consideration thereof, and authorizing the Corporation to execute and file with the Secretary of State of the State of Delaware this Certificate ...",
"Endologix Announces Approval of Reverse Stock Split IRVINE, Calif., March 5, 2019 - Endologix, Inc. previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio not less than 1 for-5 and not greater than 1-for-10 , with the exact ratio to be set within that range by the Company’s Board of Directors. The number of authorized shares of common stock would remain at 170 million shares, and the number of authorized shares of preferred stock would remain at 5 million shares. The Company’s Board of Directors had previously directed that the proposal be s..."
02/25/2019 8-K Quarterly results
02/25/2019 8-K Quarterly results
02/20/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy